<DOC>
	<DOCNO>NCT02038842</DOCNO>
	<brief_summary>The development safe effective HIV-1 vaccine strategy would probably best solution ultimate control worldwide AIDS pandemic . Heterologous prime-boost immunisation today consider promising HIV prophylactic vaccine strategy . It thus relevant pursue development different candidate vaccine prime-boost vaccine strategy identify promise prime-boost combination integrate scientific inquiry trial protocol begin maximize learning opportunity .</brief_summary>
	<brief_title>Immunogenicity Safety 4 Prime-boost Combinations HIV Vaccine Candidates Healthy Volunteers</brief_title>
	<detailed_description>Phase I/II , multicenter , national , open-label , randomized trial HIV include 4 prophylactic prime-boost HIV vaccine strategy : Volunteers randomly allocate 1:1:1:1 ratio trial entry 4 parallel arm follow prime-boost strategy : Arm 1 . MVA HIV-B prime Week 0 Week 8 + LIPO-5 boost Week 20 Week 28 Arm 2 . LIPO-5 prime Week 0 Week 8 + MVA HIV-B boost Week 20 Week 28 Arm 3 . GTU-MultiHIV B prime Week 0 , Week 4 Week 12 + LIPO-5 boost Week 20 Week 28 Arm 4 . GTU-MultiHIV B prime Week 0 , Week 4 Week 12 + MVA HIV-B boost Week 20 Week 28</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Written sign inform consent Subject low risk contract HIV i.e . history inject drug use previous ten year ; gonorrhea syphilis last six month ; high risk partner ( e.g . inject drug user , HIV positive partner ) either currently within past six month ; unprotected anal intercourse last six month , outside relationship regular partner known/presumed HIV negative ; unprotected vaginal intercourse last six month outside relationship regular known/presumed HIV negative partner Available followup duration study ( 56 week screen ) Willing undergo HIV test Willing undergo genital infection screen If heterosexually active female , use effective method contraception partner ( combined oral contraceptive pill ; injectable contraceptive ; contraceptive implant/patch ; IntraUterine Contraceptive Device ( IUCD ) ; consistent record condom use ; physiological anatomical sterility self partner ) 14 day prior first vaccination 4 month last , willing undergo urine pregnancy test prior vaccination If heterosexually active male , use effective method contraception partner first day vaccination 4 month last vaccination Subject register French Health ministry computerise file authorise participate clinical trial Subject cover Health Insurance Clinically relevant abnormality history examination include history : uncontrolled infection ; autoimmune disease ; immunodeficiency use immunosuppressive drug within 3 month prior screen ; cancer ; chronic disease require longterm treatment whose interruption trial impact health status short longterm Receipt live attenuate vaccine within 60 day vaccine within 14 day prior W0 Planned receipt vaccine plan protocol recommend France ( exclude live attenuate vaccine ) trial followup ( reference : Weekly Epidemiological Newsletter 1415 date April 10th , 2012 ( Bulletin Epidémiologique hebdomadaire 1415 / 10 avril 2012 ) ) Receipt blood product immunoglobin within 4 month prior screen History severe local general reaction vaccination define local : extensive , indurated redness swell involve anterolateral thigh major circumference arm , resolve within 72 hour general : fever ≥ 39.5°C within 48 hour ; anaphylaxis ; bronchospasm ; laryngeal oedema ; collapse ; convulsion encephalopathy within 72 hour Positive ANA antibody titer consider clinically significant : titer ≥ local cutoff associate positive antinative DNA extractable nuclear antigen antibody HIV1 HIV2 positive indeterminate screen Woman expect conceive study period Pregnant breastfeed woman Symptoms , physical sign laboratory value suggestive systemic disorder , include renal , hepatic , cardiovascular , pulmonary , skin , immunodeficiency , psychiatric , could interfere interpretation trial result compromise health volunteer Clinically significant grade 1 routine laboratory parameter Grade 2 routine laboratory parameter Known hypersensitivity aminoglycosides egg ( used vaccine production process ) Known hypersensitivity one trial vaccine component , metabolite formulation excipients Anticipated noncompliance protocol Participation another clinical trial ongoing exclusion period screen Participation HIV preventive vaccine clinical trial ( unless participant randomize placebo arm ) Subject legal guardianship incapacitation Subject active blood donor unwilling interrupt blood donation his/her participation trial</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>